NCT00275041View on ClinicalTrials.gov

Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2009

Conditions
Breast Cancer
Interventions
BIOLOGICAL

cetuximab

DRUG

irinotecan hydrochloride

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00275041 - Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter